Mongeau R, De Montigny C, Blier P
Department of Psychiatry, McGill University, Montréal, Québec, Canada.
Eur J Pharmacol. 1994 Dec 12;271(1):121-9. doi: 10.1016/0014-2999(94)90272-0.
The present study investigated the effects of various classes of antidepressant drugs (10 mg/kg per day, s.c. during 21 days) on the electrically evoked release of [3H]noradrenaline and on its modulation by the 5-HT3 receptor agonist 2-methyl-5-hydroxy-tryptamine (2-methyl-5-HT) using preloaded rat hippocampal slices. Treatments with either fluoxetine, a selective serotonin (5-HT) reuptake inhibitor, or moclobemide, a reversible type A monoamine oxidase inhibitor, increased the evoked release of [3H]noradrenaline. These two antidepressant treatments did not change, however, the magnitude of the enhancing effect of 2-methyl-5-HT on the electrically evoked release of [3H]noradrenaline. Desipramine produced a much larger increase of the electrically evoked release of [3H]noradrenaline than fluoxetine or moclobemide, and desensitized the 5-HT3 receptors that modulate this release. Trimipramine, which like desipramine has a tricyclic structure but does not block the reuptake of noradrenaline or that of 5-HT, did not increase the evoked release of [3H]noradrenaline and did not desensitize the 5-HT3 receptors that enhance the release of [3H]noradrenaline. Maprotiline, a selective noradrenaline reuptake inhibitor, did not produce the same changes as desipramine, but maprotiline inhibited noradrenaline reuptake to a lesser extent (50%) than desipramine (80%). These results suggest that the high potency noradrenaline reuptake blocker desipramine desensitizes 5-HT3 receptors modulating [3H]noradrenaline release, but that this effect is not common to all antidepressant drugs.
本研究使用预先装载的大鼠海马切片,研究了各类抗抑郁药物(每天10毫克/千克,皮下注射,持续21天)对电诱发的[3H]去甲肾上腺素释放的影响,以及5-HT3受体激动剂2-甲基-5-羟基色胺(2-甲基-5-HT)对其的调节作用。用选择性5-羟色胺(5-HT)再摄取抑制剂氟西汀或可逆性A型单胺氧化酶抑制剂吗氯贝胺进行治疗,可增加[3H]去甲肾上腺素的诱发释放。然而,这两种抗抑郁治疗并未改变2-甲基-5-HT对电诱发的[3H]去甲肾上腺素释放的增强作用的幅度。地昔帕明比氟西汀或吗氯贝胺产生的电诱发[3H]去甲肾上腺素释放增加幅度大得多,并使调节这种释放的5-HT3受体脱敏。与地昔帕明一样具有三环结构但不阻断去甲肾上腺素或5-HT再摄取的曲米帕明,并未增加[3H]去甲肾上腺素的诱发释放,也未使增强[3H]去甲肾上腺素释放的5-HT3受体脱敏。选择性去甲肾上腺素再摄取抑制剂马普替林产生的变化与地昔帕明不同,但马普替林抑制去甲肾上腺素再摄取的程度(50%)比地昔帕明(80%)小。这些结果表明,高效能去甲肾上腺素再摄取阻滞剂地昔帕明使调节[3H]去甲肾上腺素释放的5-HT3受体脱敏,但这种作用并非所有抗抑郁药物都具有。